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Clinical islet transplantation is a β-cell replacement strategy that represents a possible deﬁnitive intervention for patients
with type 1 diabetes, oﬀering substantial beneﬁts in terms of lowering daily insulin requirements and reducing incidences
of debilitating hypoglycemic episodes and unawareness. Despite impressive advances in this ﬁeld, a limiting supply of islets,
inadequate means for preventing islet rejection, and the deleterious diabetogenic and nephrotoxic side eﬀects associated with
chronic immunosuppressive therapy preclude its wide-spread applicability. Islet transplantation however allows a window of
opportunity for attempting various therapeutic manipulations of islets prior to transplantation aimed at achieving superior
transplant outcomes. In this paper, we will focus on the current status of various immunosuppressive and cellular therapies that
promotegraftfunctionandsurvivalinpreclinicalandclinicalislettransplantationwithspecialemphasisonthetolerance-inducing
capacity of regulatory T cells as well as the β-cells regenerative capacity of stem cells.
1.Introduction
Type 1 diabetes (T1D) is a T-cell-mediated autoimmune dis-
ease that involves the progressive destruction of pancreatic β
cells resulting in complete loss of insulin secretion [1]. While
a combination of genetic predisposition and autoimmune
processes contributes to its development, inﬂammatory
mediators and innate immunity play a key role in the
induction and ampliﬁcation of the immune assault as well
as in the maintenance of insulitis [2, 3]. Based on studies
using animal models of autoimmune diabetes such as the
biobreeding (BB) rat and the nonobese diabetic (NOD)
mouse,theinvolvementofβ-cellautoantigens,macrophages,
dendritic cells (DCs), and T and B lymphocytes in the
development of T1D has been established [4–6]. Antigen-
presenting cells (APCs) such as macrophages and DCs are
the ﬁrst to inﬁltrate islets followed by CD4+ and CD8+ T
lymphocytes, natural killer (NK) cells, and B lymphocytes.
Macrophages play an essential role in the development and
activation of cytotoxic CD8+ T cells, the ﬁnal eﬀectors of β-
cell destruction [5]. Studies indicate that IL-12 secreted by
macrophages may activate Th1-type CD4+ T cells and sub-
sequently IL-2 as well as other proinﬂammatory cytokines
released by the activated CD4+ T cells (for e.g., interferon-
gamma IFN-γ, tumor necrosis factor TNF-α and TNF-β)
contribute to maximizing the activation of cytotoxic CD8+
T cells. Activated CD4+ and CD8+ T cells act in unison
to activate β-cell death via apoptosis. Additionally, IFN-γ
released by CD4+ T cells may in turn activate macrophages
to release proinﬂammatory cytokines and reactive oxygen
species (ROS, e.g., superoxide, hydrogen peroxide, nitric
oxide(NO),etc.).Ultimately,T-cell-mediatedβ-celldestruc-
tion is eﬀected overall by the interplay between receptor-
mediated interactions (e.g., Fas-Fas ligand, CD40 ligand,
TNF-TNF receptor),secretionofproinﬂammatorycytokines
and ROS as well as the release of granzymes and perforin
from cytotoxic eﬀector T cells. Furthermore, DNA damage
in β-cells leads to the activation of poly (ADP-ribose)2 Journal of Transplantation
polymerasewhichrapidlydepletesNADthathasbeenshown
to be protective against radical-induced necrosis [7]. Inter-
estingly, among the regulators of apoptosis, nuclear factor-
kappaB(NF-κB)hasemergedasamasterswitchofcytokine-
induced β-cell dysfunction and death [2]. Recognition of
ligands by pattern-recognition receptors (PRRs, e.g., Toll-
like receptor TLR3/4, RigI, MDA5) on β-cells leads to the
activation of key transcription factors such as NF-κBa n d
signal transducer and activator of transcription 1 (STAT-1),
inducingthereleaseofchemokinesandcytokinesthatrecruit
and activate immune cells, increase expression of MHC class
I antigens, and activate proapoptotic signals resulting in β-
cell destruction. Proinﬂammatory cytokines further induce
STAT-1, NF-κB, and interferon regulatory factor 3 (IRF-3) in
β-cells, contributing to the maintenance and ampliﬁcation
of the immune processes that result in the progressive and
selective destruction of pancreatic β-cells [2].
Several studies indicate the potential role of cytokines in
modulating the immune response towards cytotoxic eﬀector
cell or suppressor cell dominance. T1D is thought to be a
Th1-dominance disease with type 1 cytokines such as IFN-
γ,T N F - α, IL-2, IL-12, and IL-18 actively involved in β-cell
destruction. On the other hand, cytokines such as IL-4, IL-
5 ,I L - 1 0a sw e l la sT G F - β secreted by Th2/Th3 cells are
thought to inhibit β-cell destruction. Of tremendous interest
is the recent discovery that Th17 cells are potent inducers of
tissue inﬂammation and autoimmunity and may have a role
in T1D as indicated in a study using NOD mice [8, 9]. A
humanized T1D model has now been established in NOD-
scid IL2Rγ (null) mice to study the selective destruction
of mouse islet β-cells by a human T-cell-mediated immune
response, providing a valuable tool for translational research
into T1D [10].
Data from large epidemiologic studies indicate that T1D
accounts for 5% to 10% of the total cases of diabetes
worldwide, with its incidence increasing by 2% to 5%. In
the United States, the prevalence of T1D by 18 years of age
is approximately 1 in 300 [11, 12]. Strategies to prevent or
reverse T1D are broadly based on the concepts of β-cell
regeneration, β-cell replacement, or protection of islets from
immune destruction. While regenerative strategies broadly
involve β-cell regeneration from progenitors/stem cells (e.g.,
putative β-cell progenitors/pancreatic stem cells; embryonic,
mesenchymal, hematopoietic, and umbilical cord blood-
derived stem cells (UCB-SCs), induced pluripotent stem
cells (iPSCs), etc.) or neogenesis from ductal and non-
β-cell progenitors, β-cell replacement strategies include
transplantation of whole pancreas or islets of Langerhans or
genetically engineered insulin-secreting cells.
2.Islet Transplantation
The current standard of treatment for T1D requires lifelong
exogenous insulin administration by either insulin pump
or multiple daily injections which although successful by
no means represents a cure, often resulting in hypo-
glycemic episodes and in microvascular complications in
a high percentage of patients [13]. In the year 2000, islet
transplantation was performed using the “Edmonton proto-
col” that consisted of induction therapy with a monoclonal
antibody (mAb) against the interleukin-2 (IL-2) receptor
(Daclizumab), and maintenance therapy with a calcineurin
inhibitor (CNI, Tacrolimus) and a mammalian target of
rapamycin (mTOR) inhibitor (Sirolimus). Over a followup
period of approximately 11.9 months, all patients were
insulin-free [14]. Subsequently, the reproducibility of this
protocol was demonstrated by several studies. For instance,
in 2006 an international multicenter trial demonstrated
successful restoration of endogenous insulin producion and
glycemic stability in 44% of transplant recipients at one
year following the ﬁnal islet transplantation. Persistent
graft function deﬁned by detectable C-peptide levels and
improved glycemic control was observed in 70% of the
recipients at the two-year followup although the insulin
independence rate was disappointingly low (14%) [15]. The
2008 update from the Collaborative Islet Transplant Registry
(CITR) summarizing the results from 279 recipients of one
or more islet alone allotransplants between 1999 and 2007
also reported achievement of insulin independence in 23%
of islet-alone recipients at 3-year after ﬁrst infusion (insulin
independence ≥2weeks) while 29% were insulin dependent
with detectable C-peptide, 26% had lost function, and
22% had missing data [16]. Furthermore, 70% comprising
all those with one or multiple infusions achieved insulin
independence at least once, of whom 71% were still insulin
dependent 1 year later and 52% at 2 years translating
to 50% achieving and retaining insulin independence for
1 year and 35% for 2 years for all islet-alone recipients.
These results are consistent throughout the 8 years of
followup included in the registry. A dramatic decrease in
the prevalence of hypoglycemic episodes and substantial
improvement in HbA1c levels was also observed. An increase
from 2% preinfusion to 47%–69% at year 1 post-last
infusion was observed in islet-alone recipients category with
HbA1C less than 6.5% and absence of severe hypoglycemic
episodes. Factors favoring the positive primary outcomes
included amongst others a higher number of infusions,
greater number of total islet equivalents infused, lower pre-
transplant HbA1c levels, related processing/infusion centers,
islet viability more than 87%, larger islet size, and the
use of protocols with daclizumab, etanercept or calcineurin
inhibitors in the immunosuppressive regimens [16]. In fact,
while successful islet transplantation outcomes have also
been reported using islets isolated from a single donor [17,
18], Matsumoto et al. were the ﬁrst to perform successful
living donor islet transplantation to a recipient having brittle
insulin-dependent diabetes with hypoglycemic unawareness
[19]. Results obtained from recipients of autologous islet
transplantation after pancreatectomy at the University of
Minnesotta demonstrated a remarkably limited rate of
decline of insulin independence despite infusion of a lower
β-cell mass [20]. Of 173 islet autotransplant recipients,
insulin independence was achieved in 32% within the ﬁrst
year. Of those with insulin independence, 74% remained
insulin independent at the 2-year followup, 46% at 5 years
and 28% at 10 years. These results are remarkably higher
than the CITR data and highlight the strong impact ofJournal of Transplantation 3
autoimmuneandalloimmuneinjuryongraftsurvivalintype
1 diabetics receiving an infusion of allogeneic islets [16, 20,
21]. The Edmonton protocol can also be applied to patients
undergoing either islet after kidney (IAK) or simultaneous
islet kidney (SIK) procedures resulting in a high rate of graft
function and insulin independence, although the morbidity
ishigherwhencomparedtopatientsundergoingsolitaryislet
transplantationforbrittleT1D[22].Infact,animprovement
in cardiovascular function for up to 3 years of follow-up
was observed in type 1 diabetic patients with end-stage renal
disease (ESRD) receiving an IAK transplant compared with
the kidney-only group. Also improvements in kidney graft
function, survival rates, and stabilization of microalbumin-
uria among uremic patients [23]a sw e l la sa ni m p r o v e m e n t
in vascular diabetic complications [24] were observed fol-
lowing IAK transplantations. Currently, several Phase I and
Phase II clinical trials to study IAK in T1D are ongoing
(ClinicalTrials.gov Identiﬁer: NCT00708604; NCT00888628;
NCT01123187; NCT00468117). Although restoration of
endocrine function and glucose homeostasis can be achieved
by transplantation of either whole pancreas or islets of
Langerhans, each procedure has distinct advantages over
the other. While whole pancreas transplantation has been
shown to be very eﬀective at maintaining an euglycemic
state over a sustained period of time providing the graft
recipient an opportunity to beneﬁt from the improvement
of blood glucose control, it is associated with a signiﬁcant
risk of surgical and postoperative complications [25]. Islet
transplantation on the other hand, oﬀers substantial beneﬁts
in terms of being minimally invasive, reducing incidences of
debilitating hypoglycemic episodes/hypoglycemic unaware-
ness, lowering daily insulin requirements, improving levels
of glycated hemoglobin, and aﬀording potential insulin
independence [26–28]. Furthermore, it allows a window
of opportunity for attempting various therapeutic manip-
ulations of islets prior to transplantation aimed at achiev-
ing superior transplant outcomes. However, despite the
impressive advances in this ﬁeld, a limiting supply of islets,
inadequate means for preventing islet rejection and the dele-
terious diabetogenic and nephrotoxic side eﬀects associated
with chronic immunosuppressive therapy preclude its wide-
spread applicability. Also, long-term insulin independence in
islet transplant recipients is frequently lost by the ﬁfth year
of followup [29]. Nonetheless, the overall positive impact of
islet transplantation on metabolic control in T1D continues
to spur eﬀorts worldwide to develop new strategies directed
atachievinglong-lastinginsulinindependencefollowingislet
transplantation.
2.1. Immune Strategies That Promote Engraftment and
Function of Transplanted Islets. Current challenges to suc-
cessful transplantation include amongst others (a) the
loss of functional islet mass resulting from nonspeciﬁc
inﬂammatory responses as well as from preexisting and/or
transplant-induced, autoimmune-mediated islet destruction
and alloimmune rejection and (b) the failure of the newly
transplanted islets to revascularize successfully resulting in
ineﬃcient engraftment and primary dysfunction of islets.
Herein, we will review some of the various preclinical and
clinical eﬀorts to protect islet grafts from the deleterious
eﬀects of innate and adaptive allo- and autospeciﬁc immune
responses as well as to promote vasculogenesis, thereby
increasing longitudinal graft survival and function. These
strategies include amongst others immunomodulatory ther-
apies and immunosuppressive regimens. Immunomodula-
tory therapies (e.g., monoclonal antibody therapies, costim-
ulatory signaling blockade, IL-1 receptor antagonist therapy,
cellular therapies, etc.) act by (a) providing immunoregula-
torycytokinessuchasIL-4,IL-10,orTGF-βor(b)byinhibit-
ing proinﬂammatory cytokines or (c) by altering the balance
between TH1 and TH2 cells or (d) by protecting islets
from immune destruction by encapsulation and so forth.
Immunosuppressiveregimensontheotherhandactbyeither
(a) suppressing the innate and adaptive immune response
through various strategies that include binding to speciﬁc
cytoplasmic proteins that inhibit IL-2 secretion and subse-
quent T-cell expansion (CNIs Cyclosporine and Tacrolimus)
or (b) by suppressing IL-2R signaling thereby inactivating T
cells (Sirolimus) or (c) by inhibiting cell division of lympho-
cytes(Azathioprine)[30].Currently,combinatorialtherapies
that promote vasculogenesis/angiogenesis of islets and islet
regeneration/β-cell expansion and that target antigen spe-
ciﬁc/nonspeciﬁcandantibody-speciﬁcimmunomodulations
that readjust the underlying immunologic imbalance to
stop/reverse the β-cell-speciﬁc immune destruction and
maintain immune tolerance together with steroid-sparing or
-freeimmunosuppressiveregimenslackingnephrotoxicityor
diabetogenicity are of immense therapeutic value towards
generating successful islet transplantation outcomes.
2.1.1. Blocking the Instant Blood Mediated Inﬂammatory Re-
action: Pharmacologic and Encapsulation Strategies. One of
the ﬁrst inﬂammatory assaults encountered by the islets
on contact with ABO-compatible blood following trans-
plantation via hepatic portal vein is the instant blood-
mediated inﬂammatory reaction (IBMIR) [31, 32]. IBMIR
is a thrombotic reaction characterized by activation of both
the coagulation and complement cascades that results in
the disruption of islet morphology and function, posing a
serious obstacle to successful islet engraftment. Activation
of the complement and the generation of anaphylatoxins
C3a and C5a leads to recruitment of polymorphonuclear
(PMN) leukocytes, upregulation of adhesion molecules on
the endothelium and platelets, generation of ROS, and
induction of cytokine release [33, 34]. Islets themselves
secrete both tissue factors (TFs) that trigger IBMIR [35]a n d
chemokines including monocyte chemoattractant protein 1
(MCP1), chemokine C-X-C motif ligand 8(CXCL8), and
chemokineC-Cmotifligand2(CCL2)thatmightparticipate
in recruitment of PMNs and monocytes/macrophages to the
site of engraftment [36–39]. In fact, a signiﬁcant association
between TF and CCL2 released in vitro by islets and
biochemical indices of coagulation was observed in patients
after islet transplantation [36] indicating that reduction of
the islet proinﬂammatory state may be a means to reduce the
earlyposttransplantcomplicationsandpossiblyimproveislet4 Journal of Transplantation
engraftment. To this end, strategies attempted for improving
β-cell graft survival include the use of OptiPrep gradient
media during puriﬁcation of human islets. This media
has been shown to signiﬁcantly reduce cytokine/chemokine
production including IL-1β,T N F - α,I F N - γ,I L - 6 ,I L - 8 ,M I P -
1β, MCP-1, and RANTES during the 48-hour culture after
isolation thereby improving β-cell survival during pretrans-
plant culture [40]. Similarly, embedding mouse islets in
reconstituted basement membrane extract (BME) for 24 or
48hours partially protected islets from anoikis by decreasing
caspase-3 levels and increasing α3 integrin, focal adhesion
kinase (FAK) protein level, and FAK activity suggesting
a beneﬁcial role in preservation of viability and function
of isolated islets. Furthermore, expression of transcription
factor pancreatic and duodenal homeobox 1 (PDX-1) was
preserved at 48 hours indicating a positive contribution of
BME to cell activity [41].
Pioneering work has been done by the group of Nilsson
and Korsgren in developing clinically applicable strategies to
inhibit the activation of the coagulation and complement
systems and the inﬁltration of leukocytes into islets that
characterize the IBMIR. For instance, they demonstrated
the eﬀectiveness of low MW-dextran sulphate in inhibiting
IBMIR in a nonhuman primate model of pancreatic islet
transplantation, providing the basis for a protocol that can
be used to abrogate the IBMIR in pig-human clinical islet
xenotransplantation [32]. As a result of their studies, a
clinical trial to assess the safety and eﬃcacy of LMW-sulfated
dextran on posttransplant islet function in people with T1D
is ongoing (ClinicalTrials.gov Identiﬁer: NCT00790439).
They also developed a biotin/avidin technique to conjugate
preformed heparin complexes to the surface of islets that
protected against intraportal thrombosis and inhibited the
IBMIR without increasing the bleeding risk or inducing
acute or chronic toxicity in the islets [35]. On a similar
principle, they demonstrated that human aortic endothelial
cell- (EC-) coated islets reduced activation of coagulation
and complement, platelet/leukocyte consumption in blood
as well as inﬁltration of CD11b+ cells [42, 43]. Furthermore,
addition of mesenchymal stem cells (MSCs) to this compos-
ite indicated enhanced EC proliferation, sprout formation,
and ingrowth of ECs into the islets demonstrating the
clinical potential of composite EC-MSC islets in improving
islet angiogenesis, revascularization, and immune regulation
[44]. Optimizing the EC-islet coculture methods to enable
human EC coating of pig islets would oﬀer new strategies to
improve xenogenic islet transplantation outcomes. Recently,
immobilization of human soluble complement receptor
1 (sCR1) on the islet cell surface through poly(ethylene
glycol)-conjugated phospholipid (PEG-lipid) was shown to
eﬀectively inhibit complement activation and protect islets
against attack by xenoreactive antibodies and complement
without loss of islet cell viability or insulin secretion ability,
demonstrating an eﬃcient means to control early islet loss
in clinical islet transplantation [45]. Coating islet surfaces
with PEG-lipid followed by further modiﬁcation with a
ﬁbrinolytic enzyme urokinase further increased the eﬃcacy
of this procedure [46, 47]. These reports highlight the
potential of tissue-targeted chemistry to reduce donor-cell-
mediated procoagulantandproinﬂammatory responses. The
anaphylatoxin C5a elicits a broad range of proinﬂammatory
eﬀects and most likely plays a crucial role in IBMIR. In
a recent mouse intraportal islet transplant study, Satomi’s
group demonstrated that C5a inhibitory peptide (C5aIP)
signiﬁcantly suppressed the thrombin-antithrombin com-
plex formation, improving both curative rate and glucose
tolerance as well as signiﬁcantly suppressing the expression
of TF on granulocytes in recipient livers [48]. Suppression of
TFexpressionattenuatedcross-talkbetweenthecomplement
and coagulation cascades leading to improvement in islet
engraftment indicating that C5aIP therapy in combination
withconventionalanticoagulantscouldrepresentabeneﬁcial
intervention in clinical islet transplantation. Similar reduc-
tion in the expression of TF and MCP-1 in human islets
was demonstrated by the addition of nicotinamide to the
culture medium in an in vitro loop model [49]. Surface
reengineering of pancreatic islets with recombinant azido-
thrombomodulin also resulted in a signiﬁcant reduction in
islet-mediated thrombogenicity [50]. Nilsson’s group had
alsodemonstratedthatadministrationofaspeciﬁcthrombin
inhibitor Melagatran signiﬁcantly reduced IBMIR in vitro in
a dose-dependent manner [51] as did sCR1/heparin ther-
apy [52, 53] or TP10/immune-suppressive drug treatment
following intraportal transplantation of porcine islets to
cynomlogus monkeys [54]. Other anticoagulant or com-
plement inhibitors to block IBMIR in preclinical studies
include N-acetyl L-cysteine that eﬃciently inhibited the
procoagulant activity of human recombinant TF in human
islet cell preparations at clinically relevant concentrations
without cellular toxicity [55].
Fetal and neonatal porcine islets express a cell sur-
face antigen containing the epitope—Galα1—3Galβ1—
4GlcNAc-R (“α-gal”) to which humans have complement
ﬁxing antibodies that cause immediate rejection of trans-
planted islets [56–59]. This response may be prevented
by (a) inhibition of the functional “α-gal” activity using
knockout [60] or knockin procedures involving human
alpha (1,2)-fucosyltransferase [61] or N-acetyl-glucosaminyl
transferase III gene expression [62] or (b) by depletion of
anti-pigantibodiesorcomplementfromserumor(c)theuse
of GT knockout (α1,3-galactosyltransferase gene knockout
[GTKO]) pigs [63] as the sources of islets. Expression of
thrombomodulin [64], TF pathway inhibitor [65], CD39
the endothelial ecto-nucleoside triphosphate diphosphohy-
drolase, and haem oxygenase also demonstrate potential
value for coagulation control in pig-to-human xenotrans-
plantation. Prevention of coagulation dysfunction [66]o r
expression of human complement-regulatory proteins such
as CD46 (membrane cofactor protein) [67, 68], human
decay accelerating factor (DAF, CD55) [64, 69], CD59 [70–
72] or all three [73]; or expression of anticoagulant and
antiplatelet molecules within the graft may also aﬀord
some protection [57]. For instance, adenovirus-mediated
expression of the human complement regulatory proteins
DAF (CD55) or CD59 protected adult porcine islets from
complement-mediated cell lysis by human serum [74]a s
did a low-molecular mass factor VIIa (FVIIa) inhibitor that
indirectly blocked both membrane bound and alternativelyJournal of Transplantation 5
spliced forms of TF in vitro [75]. Recombinant antithrombin
III may also ameliorate both early graft damage and the
development of systemic coagulation disorders in pig-to-
human xenotransplantation [76]. These strategies in parallel
with physical methods such as encapsulation may contribute
signiﬁcantly in reducing the thrombogenicity of pig islet
xenografts.
Several intravascular and extravascular devices involving
encapsulation technology to overcome destruction of the
graft by immune cells and large antibodies have been
described. While intravascular macrocapsules are anasto-
mosed to the vascular system as AV shunt, extravascular
macrocapsules are mostly diﬀusion chambers transplanted
at diﬀerent sites and extravascular microcapsules are trans-
planted in the peritoneal cavity. The major advantage of
the intravascular device is that direct contact with the
blood stream ensures ample oxygen and nutrient supply
enhancing graft survival and function. Use of vascularized
bioartiﬁcial devices was among the few cases that obtained
long-term allo- and xenogeneic islet survival in totally
pancreatectomized dogs [77, 78]. However, thrombosis is a
major challenge, requiring intense anticoagulation therapy.
The extravascular devices on the other hand oﬀer minimal
surgical risk, transplantation at extrahepatic sites, lack of
thrombosis, and ease of retrieval from recipient in case
of pericapsular ﬁbrotic overgrowth. Both these devices
however remain vulnerable to small molecules such as
cytokines/chemokines and nitric oxide as well as hypoxic
stress. Coencapsulation of islets with various agents such
as erythrocytes [79] and sertoli cells [80] that release
immunosuppressive factors or with factors that enhance
revascularization such as vascular endothelial growth factor
(VEGF) [81], photosynthetic oxygen generator algae [82]
and so forth or with factors like bioengineered insulin-like
growth factor-II (IGF-II) [83] that promote pancreatic β-
cell survival have been shown to improve insulin secre-
tion and glycemic control posttransplantation. Naturally
obtained alginate hydrogels are most widely used in islet
transplantation with barium alginate demonstrating long-
term immunoprotection in both allo- and xenotransplan-
tation settings. For instance, a signiﬁcant decrease in the
secretion of MCP1 and improvement in the islet activity
was observed when SD rat islets were microencapsulated
with novel sulfated glucomannan barium alginate (SGA)
and allotransplanted intraperitoneally into diabetic Lewis
rats [84]. Similar immunoprotection was observed when
islets co-encapsulated with angiogenic protein in permse-
lective multilayer alginate-poly-L-ornithine-alginate micro-
capsules were transplanted into an omentum pouch [85].
An extravascular (subcutaneous) transplant macrochamber
called the “βAir” device, consisting of islets immobilized in a
thin alginate-impregnated, hydrophilized Teﬂon membrane
and simultaneously supplied with oxygen by daily refueling
with oxygen-CO2 mixture provided immunoprotection and
sustained islet viability and function following allogeneic
subcutaneous transplantation into healthy minipigs [86].
Transplantationofporcineisletsmicroencapsulatedinhighly
puriﬁedbariumalginateintostreptozotocin-(STZ-)induced
diabetic Wistar rats resulted in long-term normoglycemia
without immunosuppression [87]. Thus, by providing a
solution to the hurdles of immunological rejection and the
risk of infection with porcine pathogens in clinical xeno-
islet transplantation [88], the use of encapsulation devices
may help to circumvent the shortage of allogeneic human
donor organs [56]. Alginate macroencapsulation of pig islets
was also shown to correct STZ-induced diabetes in primates
up to 6 months without immunosuppression [89]. In a
pilot clinical trial wherein microencapsulated human islets
were transplanted into the central abdominal region of
non-immunosuppressed patients with T1D, improvement in
glycated hemoglobin and the disappearance of hypoglycemia
was observed, although the patients remained on insulin
therapy [90]. In a very recent clinical study, Elliot et al.
demonstrated transitory insulin independence of several
months duration using the microencapsulation technique
[56]. Interestingly, the treatment appeared to signiﬁcantly
decrease severe hypoglycemic episodes and reduce/abolish
hypoglycemic unawareness episodes, even in the absence
of insulin independence. Evidence of xenosis in the xeno-
transplants recipients though diligently sought could not be
found.
2.1.2. Immunotherapeutic Strategies Targeting the Non-Anti-
gen Speciﬁc Immune Response. Approximately 60% of trans-
plantedpancreaticislettissueundergoesapoptosiswithinthe
ﬁrst several days in experimental models of syngeneic islet
transplantation [13, 91, 92]. Inﬁltration of graft by PMNs
and tissue macrophages and elevated levels of proinﬂam-
matory cytokines following islet transplantation strongly
suggest the involvement of nonspeciﬁc innate inﬂamma-
tory events in mediating cellular injury. Other mediators
involved in the early loss of pancreatic islets include NO,
prostaglandins (PGs), and reactive oxygen intermediates
(ROIs) [92, 93]. Several studies indicate that inhibition
of non speciﬁc inﬂammation improves the function and
survival of islet grafts. For instance, Yasunami’s group
demonstrated that V-alpha14 NKT cell-triggered IFN-γ
production by Gr-1+CD11b+ cells mediated early graft loss
of syngeneic transplanted islets [94]. Adenosine adminis-
tration suppressed NKT cell-mediated IFN-γ production
of neutrophils in the livers of graft-recipient mice, leading
to prevention of early loss of transplanted syngeneic and
allogeneic islets. Similar results were observed in a recent
study wherein recipients receiving ATL therapy (ATL146e
or ATL313) achieved normoglycemia more rapidly than
untreatedrecipientsfollowingsyngeneicislettransplantation
indicating improved survival and functional engraftment
of transplanted marginal mass of islets [91]. Histological
examination of grafts suggested reduced cellular necrosis,
ﬁbrosis, and lymphocyte inﬁltration in agonist-treated ani-
mals. Administration of adenosine A(2A) receptor agonists
also improved in vitro glucose-stimulated insulin secretion
(GSIS) by an eﬀect on leukocytes, suggesting a potentially
signiﬁcantinterventionalstrategyforreducinginﬂammatory
isletlossinclinicaltransplantation.Asimilarbeneﬁcialeﬀect
associated with reduction in inﬂammatory cell inﬁltration
and β-cell death by apoptosis was observed following6 Journal of Transplantation
administration of diannexin [95]. Sequential combination of
a JNK inhibitor SP600125 and nicotinamide plus simvastatin
also protected porcine islets from peritransplant apoptosis
and inﬂammation [96]. This combination therapy increased
β-cell viability index and viability of porcine islets cultured
overnight as well as signiﬁcantly increased the islet survival
rate in vivo. Intraductal administration of JNK inhibitor
signiﬁcantly suppressed mRNA expression levels of IL-1β,
IFN-γ,T N F - α, IL-6, IL-8, and MCP-1 in vivo and also
decreased the concentration of IL-1β and IL-8 in culture
supernatant in vitro possibly representing an alternative
target for suppression of porcine islet inﬂammation. Very
recently,administrationofbilirubintoowasshowntoreduce
the serum levels of inﬂammatory mediators including IL-1β,
TNF-α, soluble intercellular adhesion molecule 1 (ICAM1),
MCP-1 and NO, inhibit the inﬁltration of Kupﬀer cells into
islet grafts, restore insulin-producing ability of transplanted
islets and enhance glucose tolerance in diabetic mouse
recipients [97]. IL-1β plays a key role in causing pancreatic
islet dysfunction and apoptosis [92]. Through a cascade
of intracellular events, IL-1β secreted by neutrophils and
macrophages was shown to down-regulate GLUT2, up-
regulate inducible NO synthase (iNOS) and cyclooxygenase-
2, and activate NF-κB which in turn mediated the transcrip-
tion of a multitude of genes, including IL-1, IL-6, TNF-α,
ICAM-1, VCAM-1, ELAM-1, iNOS, PGE2, COX-2, and EP3
[92, 97–99]. The inhibition of IL-1β induced COX-2 and
EP3 gene expression by sodium salicylate [99]a sw e l la so f
iNOS and COX-2 tyrosine kinase were all shown to enhance
pancreaticisleβ-cellfunction[100].AlsodeﬁciencyofNOX2
decreasedROI/proinﬂammatorycytokineproductionandβ-
cell apoptosis, thereby protecting against STZ-induced β-cell
destruction and development of diabetes in mice [101].
Inhibition of Toll-Like Receptor (TLR) Signaling. Af a m i l yo f
10 functional, human, innate, immune signaling receptors
called TLRs plays an important role in the host’s innate
defense as well as adaptive immunity. Recognition of
conserved pathogen-associated microbial patterns (PRRs)
stimulates speciﬁc TLRs on APCs and T lymphocytes to
induce proinﬂammatory cytokines, chemokines, and inter-
ferons. The endogenous TLR ligands include amongst others
peptidoglycan, extradomain A of ﬁbronectin, lipopolysac-
charide, heparan sulfate, hyaluronan, high-mobility group
box protein 1 (HMGB1), Hsp60, exogenous products such
as bacterial lipoprotein, CpG DNA, ﬂagellin, and double
stranded viral RNA [102–105]. Murine islets constitutively
express TLR2 and TLR4, and TLR activation upregulates
intra-islet production of cytokines and chemokines. A recent
study indicated that TLR2 and TLR4 signaling could initiate
islet graft failure and that HMGB1 was an early mediator
[106]. Following transplantation into STZ-induced diabetic
syngeneic mice, islets exposed to LPS or peptidoglycan had
primary graft failure caused by recipient CD8+ T cells with
intra- and peri-islet mononuclear cell inﬂammation. NFκB
activation in stressed islets was prevented in the absence
of both TLR2 and TLR4. Transplantation of TLR2/4(−/−)
islets reduced proinﬂammatory cytokine production and
improvedisletsurvival.Yetanotherstudyindicatedthatearly
intraportal islet graft failure in mice was associated with
increased proinﬂammatory cytokines, HMGB1 expression,
NFκB activation, caspase-3, and TUNEL-positive cells [107].
Deﬁciency of TLR4 in donor, but not in recipient, inhibited
NFκB activation, reduced proinﬂammatory cytokines and
improved viability of islet grafts. Blockade of HMGB1 with
anti-HMGB1 monoclonal antibody (mAb, 2g7) inhibited
inﬂammatory reactions as evidenced by reduced TNFα
and IL-1ss production and improved islet viability. Thus,
these results indicate that inhibition of TLR4 activation
represents a novel strategy to attenuate early graft failure
following intraportal islet transplantation. Matsuoka et al.
demonstrated that mice HMGB1 receptors TLR2 or receptor
f o ra d v a n c e dg l y c a t i o ne n dp r o d u c t s( R A G E )b u tn o tT L R 4 ,
failed to exhibit early islet graft loss [108]. Mechanistically,
HMGB1 stimulated hepatic mononuclear cells (MNCs) in
vivoandinvitro,upregulatedCD40expressionandenhanced
IL-12 production by DCs, leading to NKT cell activation
and subsequent NKT cell-dependent augmented IFN-γ pro-
duction by Gr-1+CD11b+ cells. Treatment with either IL12-
or CD40L-speciﬁc antibodies prevented early islet graft loss.
Also, treatment with a HMGB1-speciﬁc antibody inhibited
IFN-γ production by NKT cells and Gr-1+CD11b+ cells
followingintraportalislettransplantation,indicatingthatthe
HMGB1-mediated pathway was a potential interventional
target for improving the eﬃciency of islet transplantation.
Protection by Suppressor of Cytokine Signaling (SOCS). The
protectiveeﬀectofsuppressorofcytokinesignalling(SOCS)-
3 in mouse and rat islets subjected to cytokine stimulation
has been characterized by Rønn et al. [109]. Using mice
with β-cell-speciﬁc Socs3 expression as well as a Socs3-
encoding adenovirus construct, a signiﬁcant resistance to
cytokine-induced apoptosis and impaired insulin release was
demonstrated by the transgenic islets. GSIS, insulin content
or glucose oxidation were not aﬀected by SOCS3. Rat islet
cultures transduced with Socs3-adenovirus too displayed
reduced cytokine-induced NO and apoptosis associated with
inhibition of the IL1-induced NFκB and mitogen-activated
protein kinase (MAPK) pathways. While transplanted Socs3
transgenic islets were not protected in diabetic NOD mice,
they did show a prolonged graft survival when transplanted
into diabetic allogeneic BALB/c mice indicating that SOCS3
may represent a target for pharmacological or genetic engi-
neering in islet transplantation for treatment of T1D. A more
recent study using chimeric adenovirus vector (Ad5F35-
SOCS1) to enhance SOCS1 expression in isolated Sprague-
Dawley rat islets indicated decreased levels of active caspase
3 and intranuclear apoptosis inducing factor (AIF) after
treatment with TNF-α and cyclohexamide in vitro [110].
Caspase 3 is the central executioner caspase activated by
upstreamcascadesinacaspase-dependentapoptosispathway
while AIF is a key mitochondrial protein that translocates
to the nucleus in a caspase-independent apoptosis pathway.
Transplantation of Ad5F35-SOCS1-infected islets into STZ-
induced diabetic recipients resulted in signiﬁcantly pro-
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activation and AIF translocation to nucleus was observed in
Ad5F35-SOCS1-infected islet grafts in the early posttrans-
plant period indicating that SOCS1 mediated protection of
islet grafts from apoptosis through caspase-3-dependent and
AIF-caspase-independent pathways [110]. These results were
supported by another study in which transgene expression
of SOCS-1 rendered islets signiﬁcantly more resistant to
cytokine-induced cell death after treatment with TNF-α
alone and in combination with IFN-γ [111]. Furthermore
this resistance could be correlated with signiﬁcant inhibition
of the transcription factor interferon regulatory factor-1
(IRF-1), reﬂecting enhanced cell survival signals as well as
impairment of IFNγ-induced class I MHC upregulation [93,
111]. Importantly, SOCS1-Tg islets signiﬁcantly reversed
STZ-induceddiabetesindicatingthatintragraftexpressionof
SOCS1 rendered islets insensitive to the deleterious eﬀects
of cytokines; a ﬁnding of potential signiﬁcance in the
development of therapies against acute allograft rejection
[111].
Protection by X-linked Inhibitor of Apoptosis Proteins (XIAPs).
Adenovirally delivered, transient overexpression of X-linked
inhibitor of apoptosis proteins (XIAPs) in a growth-
regulatable β-cell line (βTC-Tet) indicated that in vitro,
XIAP-expressing βTC-Tet cells were markedly resistant to
apoptosis in an ischemia-reperfusion injury model system as
well as following exposure to cytokines [112]. Subcutaneous
transplantation of these Ad-XIAP transduced βTC-Tet cells
into immunodeﬁcient mice resulted in reversal of diabetes in
3d a y sa sv e r s u s2 1d a y sf o rA d - βGal transduced control cells.
These results were recapitulated in a recent study wherein
XIAP overexpression inhibited β-cell apoptosis in syngeneic
islet transplants, reducing the number of islets as well as
decreasing the number of days required to restore eug-
lycemia,therebyraisingthepossibilitythatexvivoXIAPgene
transfer in islets prior to transplantation had the potential
to increase donor islet mass available for transplantation by
allowing more eﬃcient use of the limited existing supply of
humanisletstherebyenhancinggraftfunctionandlong-term
transplant success [113]. In comparison with this adenoviral
delivered gene transfer approach, a “nonviral” approach was
recently described involving the transfection of IDO cDNA–
containing plasmids into rat islets using Lipofectamine.
Indoleamine 2,3-dioxygenase (IDO) is an enzyme that plays
a critical role in suppressing T-cell responses inducing
fetomaternal tolerance [114]. Allotransplantation of IDO
expressing islets into STZ-induced diabetic Lewis rats was
shown to reverse diabetes and maintain glucose metabolic
control. Also, survival of IDO-transfected islet allografts
transplanted without any immunosuppression was superior
to that observed in diabetic rats receiving nontransfected
islets.
Protective Eﬀect of Haem Oxygenase-1 (Ho-1, Hmox1). Over-
expression of the cytoprotective protein haem oxygenase-
1 (HO-1) has been shown to reduce the deleterious eﬀects
of cytokine-induced apoptosis and oxidative stress in trans-
plantable islets [115–118]. For instance, HO-1 upregulation
by protoporphyrins (Cobalt-protoporphyrin CoPP, Ferrous-
protoporphyrin FePP), powerful inducers of the HO-1, in a
murine insulinomae β-TC3 cell line and in freshly isolated
murine islets was shown to exert a protective eﬀect from
apoptosis induced in vitro with proinﬂammatory cytokines
[115, 116]o rF a se n g a g e m e n t[ 117], while in vivo HO-
1u p r e g u l a t i o nr e s u l t e di ni m p r o v e di s l e tf u n c t i o ni na
syngeneic model of marginal mass islet transplantation in
rodents [118]. These results were supported by a similar
study in which CoPP treatment of donor mice for the
induction of HO-1 beginning one-day prior to islet iso-
lation plus a 9-day posttransplantation course resulted in
enhanced engraftment of syngeneic islets and improved
blood glucose levels and glycemic control [119]. Short-
course peritransplant administration of CoPP also led to
long-term DBA/2 islet allograft survival in a sizable pro-
portion of C57BL/6 mice recipients [120]. Furthermore,
preconditioning of islets with FePP alone led to improved
graft survival in untreated recipients and further increased
theproportionoflong-termsurvivinggraftsinCoPP-treated
recipients. Preconditioning also resulted in reduction of
class II expression. Peritransplant administration of proto-
porphyrins to allograft recipients also resulted in transient
powerful immunosuppression with reduced lymphocyte
proliferative responses, increased proportion of regulatory
T cells (CD4+CD25+) and decreased mononuclear cell
inﬁltrating the graft, paralleled by a systemic upregulation
of HO-1 expression, probably contributing to the induction
of donor-speciﬁc hyporesponsiveness in a proportion of the
protoporphyrin-treated animals. The transgenic expression
of haem oxygenase-1 in pancreatic β-cells of NOD mice
prolonged graft survival and aﬀorded protection from
autoimmune damage [121]. Reduced levels of proinﬂamma-
tory cytokines/chemokines, proapoptotic gene expression,
and amounts of ROS/RNS from islets were observed, with
islets more resistant to TNFα-a n dI F N γ-induced apoptosis,
providing valuable insight into the development of better
strategies for clinical islet transplantation in patients with
T1D.
Protective Regulatory Role of Interferon Regulatory Factor 1
(IRF1). A key role of IRF1 in immune-mediated β-cell de-
struction has been indicated [93]. IRF-1 is a downstream
target of IFN-β/signal transducer and an activator of
STAT-1. Deletion of IRF1 in islets was associated with a
higher prevalence of primary nonfunction, reduced insulin
secretion and shorter functioning graft survival. Cytokine-
exposed Irf1 (−/−) islets and INS1E cells transfected with
Irf1 siRNA showed increased expression of Mcp1 (Ccl2),
Ip10 (Cxcl10), Mip3α (Ccl20), and Inos (Nos2) mRNA and
elevated production of MCP-1 and nitrite compared with
controls.In vivo,Irf1( −/−)isletsdisplayedahigherpotential
toattractimmunecells,reﬂectedbymoreaggressiveimmune
inﬁltration in the grafted islets. IL-1 receptor antagonist
partly restored the cytokine-induced secretory defect in
vitro and completely prevented primary non function in
vivo. These data indicate a key regulatory role for IRF1 in
insulin and chemokine secretion by pancreatic islets under
inﬂammatory attack.8 Journal of Transplantation
Beneﬁcial Eﬀect of Redox Modulation Strategies. β-cells are
especially vulnerable to free radical and inﬂammatory dam-
age due to reduced antioxidant defenses. A recent study
was done to determine the eﬃcacy and beneﬁt of a redox
modulation strategy using the catalytic antioxidant (CA)
FBC-007 in improving islet preservation. The results indi-
cated that incubation of human islets with FBC-007 before
syngeneic, suboptimal syngeneic, or xenogeneic transplant
protected islets from STZ-induced damage and signiﬁcantly
increased their function [122]. Diabetic murine recipients
of catalytic antioxidant-treated allogeneic islets exhibited
improvedglycemiccontrolposttransplantanddemonstrated
a delay in allograft rejection. Systemic administration of
catalytic antioxidant to recipients further delayed allograft
rejection suggesting that addition of a redox modulation
strategy would be a beneﬁcial clinical approach for islet
preservation in syngeneic, allogeneic, and xenogeneic trans-
plantation.
2.1.3. Targeting Adaptive Immunity: The Eﬀectiveness of
Immunosuppressive and Tolerance-Inducing Immunothera-
peutic Strategies. Presentation of alloantigens in combina-
tion with costimulatory molecules by APCs activates signal
transduction pathways, including the calcium-calcineurin
pathway, triggering the T-cell response [21]. Subsequent
release of IL-2 amongst other molecules, activates the mTOR
pathway initiating cell proliferation and hugely expanding
the number of eﬀector T cells. Activated B lymphocytes too
produce alloantibodies against donor HLA antigens.
Costimulatory Signaling Blockade. Several studies indicate
that blockade of costimulatory signal pathways in exper-
imental transplantation models by cytotoxic T lympho-
cyte antigen-4 immunoglobulin (CTLA4Ig) or CD40LIg
enhances islet graft survival [123, 124]. For instance, human
islets infected with AdCTLA4Ig-IRES2-CD40LIg that simul-
taneously expressed CTLA4Ig and CD40LIg proteins signif-
icantly prolonged graft survival of murine islet xenografts,
downregulated expressions of Th1-cells-related cytokines,
and inhibited inﬂammatory cell inﬁltration [125]. Caspase
inhibitor therapy (EP1013) in combination with costim-
ulation blockade (CTLA4-Ig) too prevented engraftment
phase islet loss and markedly reduced islet mass required
to reverse diabetes [126]. Furthermore, EP1013/CLTA4-Ig
cotherapy signiﬁcantly increased graft survival by reducing
the frequency of alloreactive IFN-γ secreting T cells and
increasing the frequency of intragraft FoxP3+ Treg cells.
The results of these studies indicate that by minimizing
immune stimulation and reducing the requirement for
long-term immunosuppressive therapy, these combination
therapies have tremendous potential in improving clinical
transplantation.
Simultaneous blockade of CD40/CD154 and ICAM/
lymphocyte function-associated antigen (LFA)-1 also pro-
longed allograft survival [127]. Larsen’s group targeted
adhesion molecule LFA-1 that is preferentially expressed on
donor-speciﬁc memory T (TM) cells and has been impli-
cated in costimulation blockade-resistant transplant rejec-
tion [128]. Short-term induction therapy with the LFA-1-
speciﬁcantibodyTS-1/22incombinationwitheitherBasilix-
imab (an IL-2Rα-speciﬁc mAb) and Sirolimus or Belatacept
(a high-aﬃnity variant of the CD28 costimulation-blocker
CTLA4Ig) prolonged islet allograft survival in nonhuman
primates by masking LFA-1 on TM cells. Inhibition of
the generation of alloproliferative and cytokine-producing
eﬀector T cells expressing high levels of LFA-1 in vitro was
also observed. Neutralization of costimulation blockade-
resistantpopulationsofTcellswithLFA-1-speciﬁcinduction
therapy has tremendous potential in transplantation. The
eﬃcacy of Efalizumab, a blocking monoclonal antibody
directed at LFA1, as part of maintenance therapy regimen
with Sirolimus was being tested (ClinicalTrial.gov identiﬁer
NCT00672204). Efalizumab is no longer available for clinical
use. An anti-coinhibitory receptor B and T lymphocyte
attenuator monoclonal antibody (anti BTLA, PJ196) has
been reported to prolong fully MHC-mismatched cardiac
allograft survival [129]. A study testing the synergistic eﬀect
of anti-BTLA monoclonal antibody PJ196 and CTLA4Ig
costimulatory blockade in islet allotransplantation showed
that downregulation of BTLA on the surface of lymphocytes
along with accumulation of cells with regulatory pheno-
type at the graft site promoted islet allograft acceptance
indicating that this combination may prove to be an
eﬀective adjunctive strategy for inducing long-term allograft
survival. Similarly, co-stimulatory signal blocker LEA29Y
(Belatacept) has shown promising data in transplantation
s t u d i e si np r i m a t e s[ 130]. Clinical trials using LEA29Y in
islet transplantation are currently underway, for example
Clinical Islet Transplantation consortium’s clinical trial CIT-
04 is designed to study islet transplantation in type 1
diabetes with LEA29Y (belatacept) maintenance therapy
(University of Alberta, Emory University) and another
ongoing Phase II interventional study (ClinicalTrials.gov
Identiﬁer: NCT00501709) is using Belatacept for the pre-
vention of autoimmune destruction and rejection of human
pancreatic islets following transplantation for T1D. Apart
from costimulation blockade of the CD28/CD80/CD86 and
CD40/CD154 pathways as a means of inducing peripheral
tolerance, several new costimulatory molecules have been
identiﬁed in recent years including OX40 that belongs to
the TNF receptor family and is expressed on activated T
cells [131]. OX40 ligation with OX40L enhances cytokine
production, proliferation, and survival [131]. Mechanis-
tic studies indicate that anti-OX40L, treatment preserves
Treg numbers and OX40 blockade oﬀers better xenoislet
graft survival than CTLA4Ig in the spontaneous autoim-
mune NOD model, oﬀering a novel therapeutic target
for xenoislet graft protection in type 1 diabetic patients
[132]. Recently, a combination therapy consisting of anti-
CD40L, anti-OX40L, and anti-CD122 mAbs prolonged
islet allograft survival in alloantigen-primed mice [133].
This combination of mAbs also inhibited accelerated rejec-
tion mediated by donor reactive memory T cells, known
to accelerate allograft rejection, in xenoantigen-primed
mice cells by inhibiting cellular and humoral immune
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Monoclonal Antibodies. Anti-CD3 antibody has been shown
toinduce toleranceinallografttransplantation[134],reverse
autoimmunity in NOD mice [135] and slow the progression
to permanent diabetes in humans with recent-onset diabetes
[136]. In female NOD mice, oral anti-CD3 mAb was
eﬀective in reversing diabetes, allowing pregnancies and
extending longevity [135]. Treatment of diabetic transgenic
mice (NOD background) expressing the human ε chain of
the CD3 complex with Otelixizumab (an anti-human CD3
antibody) resulted in durable disease remission dependent
on transferable T-cell-mediated tolerance [137]. In single-
donor islet transplantation studies [138], anti-CD3 mAb
[hOKT3c1(Ala–Ala)]contributedtopromisingresults[139].
APhaseIIclinicaltrialstudyingtheeﬃcacyofanti-CD3mAb
in the treatment of recent onset T1D (ClinicalTrial.gov iden-
tiﬁer NCT00378508) is currently underway. Another trial
studying the eﬃcacy of hOKT3γ1 (Ala-Ala) combined with
SirolimusanddelayedTacrolimusinpromotingisletallograft
s u r v i v a lh a sj u s tb e e nc o m p l e t e d .I na na d o p t i v et r a n s f e r
model, the use of anti-CD134L mAb was shown to eﬀectively
prevent activation of CD4+ memory T cells and signiﬁcantly
prolong islet survival, similar to the manner anti-CD122
mAb prevents activation of CD8+ memory T cells [140].
Short-term administrations of a combination of anti-LFA-
1 and anti-CD154 monoclonal antibodies too induced
tolerance to neonatal porcine islet xenografts in mice [141].
The use of anti-CD134L and anti-CD122 mAbs in addition
to co-stimulatory blockade with anti-CD154 and anti-LFA-
1 prolonged secondary allograft survival in an alloantigen-
primed model and signiﬁcantly reduced the proportion of
memory T cells [142]. It also increased the proportion of
Tregs in the spleen, inhibited lymphocyte inﬁltration in the
graft, and suppressed alloresponse of recipient splenic T cells
suggesting that the combination therapy of four mAbs could
signiﬁcantly suppress the function of memory T cells and
prolong allograft survival in alloantigen primed animals.
Similar results were obtained by the same group using a
combination of CTLA4Ig, antiCD40L, anti-LFA-1, and anti-
OX40L while another study used a combination of anti-
CD40L, anti-OX40L, and anti-CD122 mAbs antibodies to
inhibit accelerated rejection mediated by memory T cells in
xenoantigen-primed mice [143].
IL-21-Targeted Therapy. The eﬃcacy of an IL-21-targeted
therapy (IL-21R/Fc, an IL-21-neutralizing chimeric protein)
onpreventionofdiabetesinNODmice,incombinationwith
syngeneic islet transplantation has recently been investigated
[144]. Results showed that IL-21-responsiveness by CD8+ T
cellswassuﬃcienttomediateisletallograftrejectionandthat
combining neutralization of IL-21 with islet transplantation
restored glucose homeostasis and resulted in recovery from
autoimmune diabetes. Since the absence of IL-21 signaling
prevented islet allograft rejection indicating a robust inﬂu-
ence of IL-21 on a graft-mounted immune response, these
ﬁndings imply that therapeutic manipulation of IL-21 may
serve as a suitable treatment for patients with T1D.
DNA Vaccination Strategy. A therapeutic DNA vaccination
strategy for autoimmunity and transplantation has also
recently been described wherein intradermal injection of
plasmid DNA encoding glutamic acid decarboxylase (GAD)
polypeptide,whichissynthesizedinbothpancreaticisletand
skin tissue, ameliorated new-onset T1D in NOD mice and
increased skin allograft survival in a BALB/c-C57BL/6 model
system in a donor-speciﬁc manner [145]. Furthermore, only
CpG-methylation of plasmid DNA coding for GAD was
required in order to signiﬁcantly increase skin allograft
survival after immunization of recipient; codelivery of a
cDNA coding for the proapoptotic BAX protein, which was
shown previously to be essential for successful therapy of
autoimmune diabetes in NOD mice by induction of FoxP3+
regulatory T cells, was not necessary. This study therefore
revealedthepromisingpotentialforautoimmunity-targeting
DNA vaccination to be applied to clinical transplantation.
Localized Immunosuppression Using Glucocorticoid Micros-
pheres. The ability of poly(D,L-lactic) acid (PLA) and
poly(D,L-lacticglycolic acid (PLGA) microspheres of the soft
corticosteroid loteprednol etabonate (LE) loaded within a
biohybrid device to provide localized immunosuppression
and reduce systemic side eﬀects over an extended period has
been evaluated in a set of early exploratory experiments with
diabetic rats receiving islet transplantation. While sustained
release of microspheres at low concentration showed no
cytotoxicity on the viability of the MIN-6 insuloma cell line
in vitro, animals treated using a biohybrid device loaded
with microspheres showed improved results compared to
those treated by delivery in solution form with an osmotic
minipump [146]. Sustained local delivery formulation for
glucocorticoidsdexamethasonephosphateandLEusingPLA
microspheres showed promise in their ability in vivo to
prolong allograft survival in rats after tapering of systemic
immunosuppression, compared to control groups [147].
Also,dosesdeliveredlocallywereapproximatelyhundredfold
smaller than those typically used in systemic treatments.
Induction of Tolerance by Regulatory T cells (Tregs). Donor
alloantigen-speciﬁc CD4+CD25+ Tregs play an important
role in inducing and maintaining tolerance to donor
alloantigens in vivo. By actively modulating or suppressing
the deleterious CD4+ and CD8+ T-cells-mediated immune
response to donor alloantigens, Tregs may prevent rejection
and mediate linked unresponsiveness [148]. In vivo, these
cells are dependent on interleukin IL-10 and CTLA4 for
functional activity. As part of clinical tolerance strategies,
theimmunosuppressive ability ofperipheral T-cell-depleting
agents such as anti-CD52 mAb Alemtuzumab (Campath-
1H) and antithymocyte globulin (ATG) have been tested in
humanswithautoimmunityandintransplantationscenarios
[139, 149]. Lopez et al. were the ﬁrst to report that ATG
but not Alemtuzumab or the IL-2R antagonists caused
rapid and sustained expansion of CD4+CD25+ T cells in
cocultures with human peripheral blood lymphocytes and
displayed enhanced expression of the regulatory markers
glucocorticoid-induced TNF receptor, CTLA4 and FoxP3 as
well as eﬃcient suppression of a direct alloimmune response
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of Tregs depended on the production of Th2 cytokines
in the generating cultures. This study demonstrated the
therapeutic potential of ATG in promoting the generation
of Tregs for cellular therapy in autoimmunity and clinical
transplantation. Recently, a clinically relevant immunoreg-
ulatory strategy based on treatment of NOD mice with
murine Thymoglobulin (mATG) and CTLA4-Ig to prevent
allo- and autoimmune activation in a stringent model of
islet transplantation and diabetes reversal was investigated.
The results revealed that transplant recipients experienced a
complete abrogation of autoimmune responses and signiﬁ-
cant downregulation of alloimmunity in response to treat-
ment [151]. Furthermore, this striking eﬀect was conﬁrmed
by 100% diabetes reversal in newly hyperglycemic NOD
mice and 100% indeﬁnite graft survival of syngeneic islet
transplantation (NODscid into NOD mice). An induction
immunosuppressive therapy regimen consisting of rabbit
ATG and the monoclonal antibody to CD20 rituximab
(Rituxan) promoted long-term islet allograft survival in
cynomolgus macaques maintained on rapamycin monother-
apy [152]. Several clinical trials aimed at studying the safety
and eﬀectiveness of islet transplantation combined with
various immunosuppressive regimens that include ATG for
treatment of type 1 diabetic individuals experiencing hypo-
glycemia unawareness and severe hypoglycemic episodes
are either completed or underway. These include amongst
others an islet after kidney transplantation trial with ATG
and etanercept (ClinicalTrials.gov Identiﬁer: NCT00468117)
and islet transplantation trials with ATG, Everolimus and
cyclosporine (ClinicalTrials.gov Identiﬁer: NCT00286624);
with Rituxan (Rituximab), Thymoglobulin (ATG), Zenapax
(Daclizumab) and Rapamune (Sirolimus) (ClinicalTrials.gov
Identiﬁer: NCT00468442); with Lisofylline, ATG, basilix-
imab, Sirolimus and Tacrolimus, (ClinicalTrials.gov Identi-
ﬁer: NCT00464555); and with Raptiva, ATG, and sirolimus
(ClinicalTrials.gov Identiﬁer: NCT00672204) amongst oth-
ers.Inarecentstudy,patientsreceivingintraportalallogeneic
islet transplants were maintained on immunosuppression
consistingofATGinductionandmaintenancewithsirolimus
or mycophenolate mofetil (MMF)and costimulation blocker
belatacept or the anti-LFA-1 antibody Efalizumab which
permit long-term islet allograft survival [153]. The results
indicated that both regimens were eﬀective and well tol-
erated, with the calcineurin inhibitor/steroid-sparing islet
protocols resulting in long-term insulin independence and
belatacept proving to be an eﬀective alternative in improving
graft function and longevity while minimizing renal and β-
cell toxicity. Because Tregs strongly suppress the immune
response in syngeneic islet transplantation and improve
graft survival and function, several approaches are now
emerging to induce/increase host Tregs activity in the
transplant setting, including amongst others, systemic TGF-
β1 therapy [154]. A recent study demonstrated that islet-
speciﬁc Treg induced from the BDC-6.9 TCR transgenic
mouse by activation of T cells in the presence of TGF-β could
suppress both spontaneous diabetes as well as transfer of
diabetes into NODscid mice by diabetic NOD spleen cells or
activated BDC-2.5 TCR transgenic Th1 eﬀector T cells [155].
In the latter transfer model, the authors demonstrated that
inﬁltration of Tregs into pancreas caused a reduction in the
number of eﬀector Th1 T cells and macrophages, and also
inhibitedeﬀectorT-cellcytokineandchemokineproduction.
Transfection of eﬀector T cells with a dominant-negative
TGF-β receptor demonstrated that in vivo suppression of
diabetes by TGF-β-induced Treg is TGF-β dependent.
Rapamycin. Rapamycin is a key component of the immuno-
suppressive regimen in clinical islet transplantation. The
impact of rapamycin, on human islet engraftment and func-
tion was assessed in 10 patients with T1D before islet
transplantation [156]. The results indicated that pretreat-
ment with rapamycin was associated with a reduction in
chemokines CCL2 and CCL3 pretransplantation and a
dampened chemokine response post-transplantation, po–
tentially improving clinical islet engraftment by an anti-
inﬂammatory mechanism. In rat-to-mouse islet xeno-
transplantation, administration of anti-CD154 mAb
and rapamycin induced Treg-mediated tolerance [157].
Rapamycin has been shown to allow expansion, prolif-
eration, and regulatory function of both murine and human
naturally occurring CD4+CD25+FOXP3+ Tregs (nTregs),
which are pivotal for the induction and maintenance of
peripheral tolerance [158]. Pothoven et al. demonstrated
that rapamycin-conditioned Balb/c donor bone-marrow-
derived DCs (BMDCs) had signiﬁcantly enhanced ability
to induce CD4+CD25+FOXP3+ iTregs of recipient origin
(C57BL/6 (B6)) in vitro under Treg driving conditions
compared to unmodiﬁed BMDCs [154]. These in vitro
induced CD4+CD25+FOXP3+ iTregs exerted donor-speciﬁc
suppression in vitro and prolonged allogeneic islet graft
survival in vivo in RAG(−/−) hosts upon coadoptive transfer
with T-eﬀector cells. The CD4+CD25+FOXP3+ iTregs also
expanded and preferentially maintained FOXP3 expression
in the graft draining lymph nodes and were able to induce
endogenousna¨ ıveTcellstoconverttoCD4+CD25+FOXP3+
T cells. Thus, rapamycin-conditioned donor BMDCs can
be exploited for in vitro diﬀerentiation into donor antigen-
speciﬁc CD4+CD25+FOXP3+ iTregs capable of eﬀectively
controlling allogeneic islet graft rejection. Strom’s group
demonstrated a triple therapy approach that combined
administration of rapamycin and agonist IL-2- and
antagonist IL-15-related cytolytic fusion proteins [159]. This
treatment promoted very long-term engraftment/tolerance
of allogeneic islets in both spontaneously diabetic NOD mice
and IL-2-deﬁcient recipients by limiting the early expansion
of activated T cells, preserving and even exaggerating their
subsequent apoptotic clearance, and further amplifying
the depletion of these activated T cells by antibody-
dependent mechanisms, while preserving CD4+CD25+
T-cell-dependent immunoregulatory networks. In T1D, Treg
activity has been demonstrated in the pancreatic lymph
node, but the in vivo activity of Tregs during suppression
in pancreas remains poorly characterized. A clinical study
wherein nTreg numbers and function were examined in a
unique set of patients with T1D who underwent rapamycin
monotherapy before islet transplantation indicated that
while rapamycin monotherapy did not alter the frequency
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production of circulating nTregs, it increased their capacity
to suppress proliferation of CD4+CD25− eﬀector T-cells
[160]. These ﬁndings demonstrate that rapamycin directly
aﬀects human nTreg function in vivo, by reﬁtting their
suppressive activity, whereas it does not directly change ef-
fector T-cell function.
Induction of Tolerance Through Suppression of TLRs. TLR2-
induced IL-6 secretion from APCs has been shown to
reverse the suppressive function of Tregs [104, 161]a n d
in combination with TGFβ-induced Th17 cells resulted in
enhanced inﬂammation [103, 104, 162, 163]a n dp r e v e n t i o n
of transplantation tolerance [163]. In a very recent study to
understand the mechanism by which diﬀerent inﬂammatory
signals aﬀect transplantation tolerance and immunity, it
was determined that TLR2 ligand peptidoglycan inhibited
FOXP3 expression in both natural Tregs (nTregs) and TGFβ-
driven adaptive Tregs (aTregs) independent of paracrine
Th1, Th2, and Th17 cytokines [104]. While TLR2-induced
inhibition of FOXP3 was independent of STAT1, STAT3,
STAT4, and STAT6, it was dependent on Myd88 and IRF.
Binding of induced IRF1 to IRF1 response elements (IRF-
E) in the FOXP3 promoter and intronic enhancers negatively
regulated FOXP3 expression to suppress Treg function.
Furthermorebyinducingdivergentchromatinchangesatthe
FOXP3 locus, inﬂammatory IL-6 and TLR2 signals regulated
Treg suppressor function and reduced graft survival in an
islet transplantation model. Schroppel’s group demonstrated
that deﬁciency of TLR4 in islet graft recipients prolonged
graft survival. Low dose rapamycin-treatment of TLR4(−/−)
recipients induced permanent and prolonged engraftment of
45% of the islet graft that was dependent on the presence
of CD4+CD25+FOXP3+ Tregs [164]. Na¨ ıve CD4+CD25−
T cells cultured with the TLR4 ligand lipopolysaccharide
showed enhanced IL-4, IL-6, IL-17, and IFN-γ secretion
andinhibitedTGFβ-inducedFOXP3+Treggeneration.These
results indicated that inhibition of recipient TLR4 activation
at the time of transplantation decreased proinﬂammatory
signals and allowed for Treg generation. Approaches such
asgeneratingTLRagonists/antagonists,creatingmonoclonal
antibody to TLRs, blocking key molecules in the signaling
pathways and downmodulating TLR signaling may be of
immense beneﬁtin the treatmentof T1D and islet transplan-
tation.
Other Tolerance Inducing Treatments. Interestingly, treat-
ment of islet graft recipients with bilirubin prolonged
islet allograft survival via a Treg-dependent manner in
which CD4+CD25+ Treg cells were necessary for tolerance
induction and graft acceptance. Bilirubin treatment also
promoted de novo generation of Tregs possibly accounting
for the observed protective eﬀects [165]. A combination
treatment of Hmox1 induction, carbon monoxide, and
bilirubin administration led to long-term survival and
tolerance toward islet allografts by promoting FOXP3+
Tregs and inducing and maintaining tolerance in the
recipient [166]. VAG539 is a water soluble derivate of
VAF347, a low-molecular-weight compound that activates
the aryl hydrocarbon receptor (AhR). Oral administration
of VAG539 promotes long-term graft acceptance and active
tolerance in Balb/c mice that receive MHC-mismatched
pancreatic islet allograft, resulting in increased frequency of
splenic CD4+CD25+FOXP3+ T cells in vivo and improved
CD4+CD25+FOXP3+ T-cell survival in vitro [167]. Interest-
ingly, transfer of CD11c+ DCs but not of CD4+ T or CD19+
B cells, from VAG539-treated long-term tolerant hosts into
mice that recently underwent transplantation resulted in
donor (C57Bl/6)-speciﬁc graft acceptance and in a signif-
icantly higher frequency of splenic CD4+CD25+FOXP3+
Tregs. Furthermore, the transfer of these CD4+CD25+
Tregs into recently transplanted mice promoted islet graft
acceptance. Also, cell therapy with in vitro VAF347-treated
bone-marrow-derived mature DCs prevented islet graft
rejection,andreducedOVA-speciﬁcT-cellresponsesinOVA-
immunized mice. Taken together these data indicate that
activation of AhR induces islet allograft-speciﬁc tolerance
through direct as well as DC-mediated eﬀects on Treg
survival and function. Transient depletion of dividing T cells
by administration of ganciclovir for 14 days, induced at the
time of allogeneic islets transplantation into diabetic trans-
genic mice that express a thymidine kinase (TK) conditional
suicide gene in T cells also resulted in allograft tolerance in
63% of treated mice accompanied by a 2- to 3-fold persistent
increase in the proportion of CD4+CD25+FOXP3+ Treg
within 3 weeks only in allograft-bearing mice. Additionally,
lymphocytes from tolerant mice could transfer tolerance
to na¨ ıve allografted recipients [168]. Similar results were
obtained after cytostatic hydroxyurea treatment in normal
mice suggesting that the transient depletion of dividing
T cells represented a novel means of immunointervention
based on disturbance of T-cell homeostasis and subsequent
increase in Treg proportion.
In Vivo and In Vitro Expansion of Tregs. Nagahama et al.
established a protocol for in vivo and in vitro alloantigen-
speciﬁc expansion of naturally arising CD4+CD25+ regu-
latory T-cells (Treg) to establish antigen-speciﬁc dominant
tolerance to allogeneic transplants [169]. They showed that
in vivo exposure of CD4+CD25+ T cells from normal
naive mice to alloantigen in a T-cell-deﬁcient environ-
ment elicited the spontaneous expansion of alloantigen-
speciﬁc CD4+CD25+ nTregs capableof suppressing allograft
rejection mediated by subsequently transferred naive T
cells, leading to long-term graft tolerance. Similarly they
demonstrated that antigen-speciﬁc expansion of nTregs can
be achievedin vitro by stimulating CD4+CD25+ T cells from
normal animals with alloantigen in the presence of high
doses of IL-2. The expanded Tregs were even capable of
suppressing secondary mixed leukocyte reaction in vitro and,
following adoptive transfer, were able to establish antigen-
speciﬁc long-term graft tolerance. Francis et al. have recently
demonstrated that graft-protective Treg arise in vivo both
from naturally occurring FOXP3+CD4+ Tregs and from
non-regulatory FOXP3−CD4+ cells [170]. Interestingly, the
induction of tolerance also inhibited CD4+ eﬀector cell
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impaired eﬀector function in vitro. Thus, by converting
potential eﬀector cells into graft-protective Tregs and by
expanding alloreactive naturally occurring Tregs, adaptive
tolerance was induced. Adoptive cell therapy using patient-
speciﬁc CD4+CD25+ Tregs as individualised medicine to
promote clinical transplantation tolerance is very promising
[171]. If this principle is to be applied to clinical tolerance
induction, strategies targeting potential eﬀector cells will
have to be investigated for successful generation of alloreac-
tive Tregs that may be critical for long-term allograft survival
without chronic immunosuppression.
The Role of Tolerance-Inducing Dendritic Cell Therapies in
Treg and TH17 Cells Interconversion. Activated CD4+ T
cells develop into Th1, Th2, or Th17 subsets based on
the cytokines they produce and distinct eﬀector functions.
Th17 cells produce IL-17A, IL-17F, Il-10, IL-22, and IL-
21 and play a role in host defense against infections, and
in inducing tissue inﬂammation in autoimmune disease
[172]. The broad distribution proﬁle of IL-17 and IL-22
receptors guarantees induction of a massive tissue reaction.
The involvement of diﬀerentiation factors (TGF-β plus IL-
6 or IL-21), the growth and stabilization factor (IL-23), and
the transcription factors (STAT3, RORγ,a n dR O R α) in the
development and stabilization of Th17 cells has recently
beenidentiﬁed[173].Th17-derivedIL-21playsanimportant
role in the ampliﬁcation of Th17 cells [8]. Based on the
evidence of immunosuppressive TGF-β participation in the
diﬀerentiation of Th17 cells, the Th17 lineage appears to
have a close relationship with CD4+CD25+FOXP3+ Tregs.
Th17 cells were shown to be involved in islet transplant
rejection, and blockade of IL-23R was shown to positively
correlate with reduction in IL-17 expression in a dose-
dependent manner [174]. While the combination of anti-
CD154 mAb and IL-23R antibody was shown to prevent
the acute rejection to some extent, no signiﬁcant diﬀerence
was observed when compared with the anti-CD154mAb
alone. RelB(lo) DCs generated in the presence of an NF-
κB inhibitor induce Tregs and suppress inﬂammation. A
very important recent study showed that while tolerizing
RelB(lo) DCs were able to signiﬁcantly inhibit diabetes
progression when administered to 4-week-old NOD mice,
IL-1β produced in response to islet autoantigen presentation
reduced the immunosuppressive capacity of Treg cells and
promoted their conversion to Th17 cells [175]. RelB(lo) DCs
exacerbated the IL-1-dependent decline in Treg function
and promoted Th17 conversion. This study highlights the
importance to entertain caution while using tolerizing
DC therapies that regulate islet autoantigen priming and
prevent diabetes and that progression past the IL-1β/IL-17
checkpoint signals the need for adapting other tolerizing
strategies.
Current Combinatorial Therapeutic Strategies in Clinical
Islet Transplantation. Currently, islet transplantation fol-
lowed by ATG/alemtuzumab (Campath-1H, monoclonal).
Anti-CD52 Ab/hOKT3γ/anti-CD25 (daclizumab) induc-
tion therapy along with a sirolimus-based, prednisone-
free maintenance regimen in combination with MMF and
low Tacrolimus as well as drugs that demonstrate power-
ful immunosuppressive/anti-inﬂammatory potency in the
absence of nephrotoxicity and diabetogenicity are under
investigation [153, 176–179]. Other drugs currently in
Phases II or III of development include Otelixizumab (anti-
CD3), Teplizumab (anti-CD3), Rituximab (anti-CD20),
Abatacept (CTLA4Ig), DiapPep 277 (heat shock protein),
and GAD and Oral Insulin amongst others. GLP-1R agonists
like exendin-4 stimulate β-cell proliferation and neogenesis
and inhibit β-cell apoptosis while DPPIV inhibitors increase
cell insulin content and are therefore of immense beneﬁt in
the above mentioned combination therapies for preserving
and expanding β-cell mass following transplantation. The
activity of potent proinﬂammatory TNFα can be inhibited
by etanercept, a recombinant TNFα receptor protein. A high
success rate of insulin independence was achieved using a
protocol in which Etanercept was administered as induc-
tion therapy following single donor islet transplantation,
in combination with Prednisone, Daclizumab, and rabbit
ATG [180–182]. Combined treatment with Etanercept and
Exenatide in addition to the Edmonton immunosuppressive
protocol was shown to reduce the number of islets needed
to achieve insulin independence [183] and improve glucose
control and graft survival in patients who needed a second
transplantation because of progressive graft dysfunction
[183, 184]. These combinatorial strategies could also include
encapsulation of islets with nanoﬁber scaﬀolds or biomatri-
ces or permselective alginate microcapsules synthesized to
release immunosuppressive drugs or drugs that stimulate
vasculogenesis/angiogenesis to improve trasnplantation out-
comes at extrahepatic sites [185].
2.1.4. Role of Immunomodulatory Stem Cells in Promoting
Graft Survival. Several studies indicate that nonimmuno-
genic multipotent MSCs apart from playing an important
role in β-cell replacement therapies owing to their versatile
diﬀerentiation and ex vivo expansion potential, are also
cytoprotective immune modulators, exerting therapeutic
eﬀects by promoting graft protection, tissue revasculariza-
tion, and β-cell survival in islet transplantation [186]. Bone-
marrow-derived MSCs (BM-MSCs) can enhance repair
and regeneration, not only by repopulating damaged tis-
sue, but also by reducing inﬂammation. Also, they allow
transplantation across MHC barriers since they do not
possess cell surface human leukocyte antigen (HLA) or
MHC class II molecules. Kim et al. evaluated the thera-
peutic potential of autologous MSCs in preventing graft
rejection following allogeneic rat islet transplantation and
demonstrated that when combined with cyclosporine A
therapy, graft survival attained more than 100 days in
33% of autologous MSCs-plus-CsA-treated recipients [187].
Splenocytes from autologous MSC-plus-CsA-treated rats
exhibited a reduced MLR proliferative response to donor
stimulators and increased IL-10 release. Interestingly, IL-10
induced by CD11b+ cells and IL-10 activated Tregs played a
role in MSC-mediated immune modulation in the rat islet
allograft. The authors demonstrated that autologous MSCs-
plus-CsA downregulated immune responses and inducedJournal of Transplantation 13
donor-speciﬁc T-cell hyporesponsiveness by reducing the
production of proinﬂammatory cytokines and inducing
anti-inﬂammatory cytokine production, especially that of
IL-10, during the early post-transplantation period. Tregs
contributed at a later phase. Thus, the combined use of
autologous MSCs and low-dose CsA exerted a synergistic
immunosuppressive eﬀect in an islet allograft model. These
results were supported by the demonstration that triple-dose
administration of either syngeneic or allogeneic MSCs was
able to prevent acute rejection and improve glycemic control
in diabetic rats receiving marginal islet mass transplantation
viatheportalvein[188].Reducedlevelsofpro-inﬂammatory
cytokines and glucose as well as low-grade rejections were
observed up to 15 days after transplantation indicating the
abilityofMSCstoprolonggraftfunctionbypreventingacute
rejection. Also the eﬃcacy of MSCs was independent of the
administration route and comparable to that of immuno-
suppressive therapy indicating that MSCs may play an
important role in preventing acute rejection and improving
graft function in portal vein pancreatic islet transplantation.
It is also noteworthy to mention that xenotransplantation
of three-dimensional spheroid bodies (SBs) formed under
specialinductionconditionsfromendometrialmesenchymal
stem-like cells (SB-EMSCs) into immunocompromised mice
with STZ-induced diabetes restored blood insulin levels to
control values and greatly prolonged the survival of graft
cells. These results suggest that EMSCs not only played a
novelroleinthediﬀerentiationofpancreaticprogenitors,but
couldalsofunctionallyenhanceinsulinproductiontorestore
the regulation of blood glucose levels. It will be interesting
to dissect the role of these cells in immunomodulation and
vasculogenesis in an in vivo transplantation model [189].
The pancreatic endocrine potential of hESC-derived
CD34+ cells has recently been demonstrated by Goodrich
et al. who transplanted sheep with these cells by in utero
intraperitoneal injections prior to development of the
immune system in the fetus so that tolerance toward foreign
antigens was acquired during gestation and persisted in
the adult [190]. In animals transplanted with diﬀerentiated
cell populations and followed up to 55 months after
transplantation, they detected human DNA and insulin
messenger RNA in sheep pancreases as well as human
C-peptide in serum. As few as 23,500 cells were able
to achieve long-term sustainable β-cell-like activity. These
results along with the absence of teratomas, combined
with the hematopoietic potential of these cells suggest that
not only do hESC-derived CD34+ cells have potential for
long-term in vivo endocrine cellular activity but could
also be used for the induction of immunological tolerance
and bone marrow chimerism prior to cellular therapy for
diabetes. A phase II islet transplantation clinical trial at the
University of Miami is currently ongoing using monoclonal
antibody Campath-1H for induction of immunosuppression
combined with the simultaneous infusion of islets with
donor CD34+ enriched bone marrow cells (ClinicalTri-
als.gov identiﬁer: NCT00315614) to reverse hyperglycemia,
induce a state of donor-speciﬁc tolerance and eliminate the
need for continuous immunosuppressive therapy. A study
to investigate the immunomodulatory role of mobilized
autologous hematopoietic stem cells (HSCs) via antagonism
of the CXCR4-CXL12 axis in promoting islet engraftment
following allotransplantation demonstrated mobilization of
HSCs and prolongation of islet graft survival that was
further enhanced by the addition of rapamycin to anti-
CXCR4 therapy, inducing a robust and transferable host
hyporesponsiveness. Mobilized HSCs expressed high levels
of the negative costimulatory molecule programmed death
ligand 1 (PDL1) and suppressed the in vitro alloimmune
response. Thus, targeting the CXCR4-CXCL12 axis mobi-
lized autologous HSCs and promoted long-term survival of
isletallograftsviaaPD-L1-mediatedmechanism.Haltingthe
CXCR4 antagonist-mediated HSC release by administration
of an ACK2 (anti-CD117) mAb restored allograft rejection
[191].
The innate anti-inﬂammatory and immunosuppressive
potential of human amniotic epithelial cells (AECs) to
create localised immuneprivilege in an in vitro islet cell
culture system as an alternative to immunosuppressive drug
therapy was investigated. Islets transduced with bioengi-
neered cellular constructs composed of human islets and
AEC (islet:AEC) demonstrated sustained, physiologically
appropriate insulin secretion and reduced mitogen-induced
PBL proliferation suggesting that transplanted islets may
beneﬁt from the immune-privilege status conferred on them
as a consequence of their close proximity to human AEC and
that this approach may reduce the need for chronic systemic
immunosuppression [192].
2.2. Enhancing Graft Survival by Promoting Vasculogenesis
and Reducing Hypoxia. In experimental islet transplanta-
tions, both blood perfusion as well as the tissue oxygen
tension of the grafted islets are chronically decreased in
the transplanted islets, indicating that reestablishment of
an appropriate microvascular supply is an essential pre-
requisite for successful islet engraftment. The islet grafts
depend upon endothelial cells and microvessels in the
implantation organ for derivation of a new vascular system
[193, 194]. Improved islet graft survival and function have
been observed on exposure to growth factors such as basic
ﬁbroblast growth factor (bFGF), endothelial cell growth
factor α and particularly VEGF, which has been known to
contributesigniﬁcantlytothevascularizationoftransplanted
islets [195]. In humans, the VEGF family of homodimeric
glycoproteins consists of VEGF-A, -B, -C, -D, and placental
growth factor [194]. Interestingly, although pancreatic islets
continuously express VEGF-A [196], upon subjection to
hypoxia following transplantation devascularized grafted
islets signiﬁcantly increase their expression of VEGF, ini-
tiating revascularization and maintaining the vascular per-
meability [196–199]. VEGF-A stimulates EC permeability
and chemotaxis through cognate VEGF receptors and is
a prerequisite for islet endothelial fenestration [194–200].
Korsgren and Magnusson’s group showed that immobiliz-
ing heparin on the islet surface was useful in achieving
complete coverage of islets with VEGF-A as a means of
attracting ECs to induce angiogenesis and revascularization,
ultimatelyimprovingisletrevascularizationandengraftment14 Journal of Transplantation
in pancreatic islet transplantation [35, 44]. A very recent
study indicates that concomitant transplantation of isolated
islets with ECs can prolong islet graft survival in diabetic rats
[201]. Cartilage oligomeric matrix protein-angiopoientin-
1 (COMP-Ang1) is a speciﬁc growth factor that induces
vascularizationviatheTie2orTie1receptor.Usinganinvitro
angiogenesis assay based on a three-dimensional collagen-
based culture system, Park et al. recently demonstrated that
the transduction of COMP-Ang1 into islets signiﬁcantly
increased angiogenesis [202]. COMP-Ang1 transduced islets
also attenuated hyperglycemia in syngeneic STZ-induced
diabetic C57BL/6 mice and enhanced glucose tolerance. In
another study, following subcutaneous transplantation of
BALB/c islets in VEGF and hepatocyte-growth-factor (HGF)
supplemented matrigel basement membrane matrix into
diabetic scid mice [203], histopathologic analysis of the
functioning grafts harvested at 15 days revealed signiﬁcantly
increased blood vessel formation and increased number of
islets.Enhancedintercellularadhesionmolecule(ICAM)and
vascular cell adhesion molecule (VCAM) within the islets
was also observed suggesting stable blood vessel formation.
Transcription factors focal adhesion kinase phosphorylation
andextracellularsignal-regulatedkinase1/2 phosphorylation
were also increased (8-fold and 4.6-fold, respectively). These
results suggest synergistic enhancement of angiogenesis by
VEGF and HGF following islet transplantation resulted in
stable engraftment. In order to drive delivery of growth
factors such as VEGF and FGF into the dense islet interior,
Chow et al. developed heparin-binding peptide amphiphile
(HBPA)/heparin nanoﬁber gels that can activate heparin-
binding, angiogenic growth factors [204]. Inﬁltration of
bioactive nanoﬁbers in the interior of islets acted as an
artiﬁcial extracellular matrix (ECM) improving cell viabil-
ity and function and enhancing their vascularization in
the presence of growth factors such as FGF2 and VEGF.
The intraislet nanoﬁbers helped retain FGF2 within the
islet for 48h and increased cell viability signiﬁcantly for
at least 7days in culture. Furthermore, enhanced insulin
secretion was observed with the nanoﬁbers for 3 days in
culture. Delivery of FGF2 and VEGF in conjunction with
the HBPA/heparin nanoﬁbers also induced a signiﬁcant
amount of islet EC sprouting from the islets into a peptide
amphiphile 3D matrix. This approach may have a signiﬁcant
impact on islet transplantation. Mahato coexpressed human
VEGF (hVEGF) and human IL-1 receptor antagonist (hIL-
1Ra) as well as human HGF (hHGF) and hIL-1Ra in
human islets using Adv-hVEGF-hIL-1Ra Adv-hHGF-hIL-
1Ra constructs to study their eﬀect on β-cell proliferation
and revascularization of islets [205]. A dose- and time-
dependent expression of hVEGF and hIL-1Ra or hHGF
and hIL-1Ra by islets was observed that led to a decrease
in caspase-3 activity and apoptosis induced by a cocktail
of TNF-α,I L - 1 β,a n dI F N - γ. Also, transduction of islets
with these bipartite Adv vectors prior to transplantation
in diabetic NODscid mice reduced blood glucose levels
and increased serum insulin and c-peptide levels. Immuno-
histochemical staining of the graft revealed positivity for
human insulin, hVEGF or hHGF, and von Willebrand factor.
Transduction with Adv-caspase-3-shRNA also prevented
islets from cytokine-induced apoptosis and improved islet
transplantation [205].
The therapeutic potential of hyperbaric oxygen therapy
(HBO) in reducing hypoxia, enhancing vessel maturation,
and improving engraftment of intraportal islet transplants
by promoting angiogenesis in the critical period following
transplantation has also been demonstrated [206]. In this
study, hyperbaric oxygenation combined with implanta-
tion of a foam dressing, vacuum-assisted wound closure
(foam+VAC) to create a prevascularized site was used to
achieve better results in microencapsulated xenogeneic cell
transplantation [206, 207]. Interestingly, following intrapor-
tal islet transplantation of porcine islets to diabetic NMRI
nu/nu mice, the combination of cytokines with hypoxia
resulted in a strong induction of cell death that could be
blocked dose-dependently by a selective IKK-β inhibitor that
caused systemic NF-κB inhibition, signiﬁcantly prolonging
islet graft survival [208]. Under hypoxia, NF-κBa c t i v i t y
impaired expression of antiapoptotic genes BCL-xL, c-FLIP
and survivin. NF-κB thus appeared to have an antiapop-
totic role under normoxia, while low oxygen conditions
decreased its activity and transformed it to a proapoptotic
transcription factor in pancreatic islets suggesting that NF-
κB inhibition represented a potential strategy to improve
islet transplantation eﬃciency. Signiﬁcant islet loss related to
reduced survival of large islets compromised by hypoxia has
been observed under standard culture conditions. In order
to improve the islet graft quality prior to transplantation,
rat islets have been cultured for 48h in a liquid-liquid
interface culture system (LICS) using perﬂuorodecalin, a
method of culture that avoids exposure of islets to rel-
ative hypoxia [209]. Results indicated that this protocol
optimised culture conditions, which preserved both islet
viability and signiﬁcantly increased their ability to engraft
successfully after intraportal transplantation and could be
used for islet transportation. Evaluating neovascularization
and correlating angiogenesis with metabolic and functional
islet graft condition in diabetic mice is a crucial aspect
in assessing graft survival. To this end, very recent stud-
ies demonstrated the successful use of dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) after
intravenous injection of gadolinium [210, 211]. MRI has
also been used to eﬀectively image isolated mouse islets
labeled with novel MRI contrast agent, chitosan-coated
superparamagnetic iron oxide (CSPIO) nanoparticles as
long as 18 weeks after transplantation as well as islets
labeled with Feridex-polyethyleneimine complex [212, 213].
A recent study using a dual-purpose therapy/imaging probe
consisting of therapeutic (siRNA targeting apoptosis-related
gene human caspase-3) and imaging (magnetic iron oxide
nanoparticles, MN) moieties showed that treatment with the
probe resulted in signiﬁcantly better survival of transplanted
islets that could be monitored by in vivo magnetic resonance
imaging (MRI) [214].
2.2.1. Stem Cells in Promoting Angiogenesis/Vasculogenesis.
Bone-Marrow-derived stem cells (BMSCs) have been shown
to promote islet graft function and survival by initiatingJournal of Transplantation 15
angiogenesis [215, 216]. A recent study involving cotrans-
plantation of bone marrow cells with islets was associated
with enhanced islet graft vascularization and function.
A signiﬁcant increase in new peri-islet vessels [216]a s
well as staining for VEGF was observed. The presence of
pancreatic duodenal homeobox-1 (Pdx-1) was detected in
BMSCs with an increase in staining over time. Protein
array measurements conducted in human islets cocultured
with whole human BM for approx. 7 months indicated
upregulated levels of angiogenesis factors VEGF-a, PDGF,
KGF, TIMP-1, and angiogenin as well as lower protein
levels of angiopoietin-2 [215]. Depletion of VEGF-a, eKGF,
and PDGF signiﬁcantly reduced islet vascularization. BM-
induced vascularization showed signiﬁcant EC distribution
and islet vascularization was linked to islet growth. Further-
more a 28.66-fold increase in insulin and 24.4-fold glucagon
gene expression was also observed. These data indicate that
BMSCsinducedendocrine cellregenerationviaregulationof
angiogenesis factors. Transplantation of genetically marked
whole bone marrow from Tie2-Cre/ZEG mice into lethally
irradiated wild-type mice evoked pronounced proliferation
of recipient ECs while signiﬁcantly increasing β-cell mass
and reducing the hyperglycemia of mice subjected to β-
cell damage by STZ [217]. A study indicated that bone
marrow cells produced nerve growth factor (NGF) and
promoted angiogenesis around transplanted islets [218].
Biochemical and histological analyses following syngeneic
cotransplantation of islets and bone marrow in STZ-induced
diabetic mice indicated signiﬁcantly low blood glucose levels
high serum insulin levels, and increased serum NGF levels.
A signiﬁcant increase in the number of vessels within
the graft area at day 14 after transplant was observed
along with improvement in graft function [218]. Thus, an
important adjuvant role of transplanted BMSCs in both
angiogenesis and β-cell regeneration has been elucidated.
Cotransplantation of pancreatic islets and adipose-tissue-
derived stem cells (ADSCs) too was shown to signiﬁcantly
prolong graft survival and insulin function of islet grafts
in diabetic mice. ADSCs have angiogenic potential and
anti-inﬂammatory properties and cotransplantation studies
indicated signiﬁcant revascularization (larger number of von
Willebrand factor-positive cells) and marked inhibition of
inﬂammatory cell inﬁltration, including CD4+ and CD8+
T cells and macrophages, in islets-ADSCs grafts [219].
Creation of a rich subcutaneous vascular network with
implanted adipose-tissue-derived stromal cells and adipose
tissue enhanced subcutaneous grafting of islets in diabetic
mice [220]. Cografting of neural crest stem cells with pan-
creatic islets in alloxan-induced diabetic mice too improved
insulin release and enhanced β-cell proliferation, resulting
in increased β-cell mass [221]. Multipotent human MSCs
possess powerful ex vivo expansion and EC diﬀerentiation
potential, placing them at the forefront in the ﬁeld of
vasculature-directed cell-based therapy and transplantation.
A recent study revealed that islets co-cultured with MSCs
demonstrated lower ADP/ATP ratios, higher GSIS indexes
and viability. Furthermore, co-cultured islets revealed higher
levels of antiapoptotic signal molecules (XIAP, Bcl-xL, Bcl-
2, and heat shock protein-32), increased VEGF receptor
2 and Tie-2 mRNA expression and elevated levels of
phosphorylated Tie-2 and focal adhesion kinase protein
[222]. Islets cultured in MSC-conditioned medium (MSC-
CM) for 48hr signiﬁcantly lowered blood glucose levels
and demonstrated enhanced blood vessel formation upon
transplantation into STZ induced diabetic mice. Signiﬁcant
levels of IL-6, IL-8, VEGF-A, HGF, and TGF-β were detected
in MSC-CM suggesting that the trophic factors secreted by
human MSCs enhanced islet survival and function after
transplantation.Similarimprovementofisletgraftmorphol-
ogy and function attributable in part to the promotion of
graft revascularization was observed when Lewis rat islets
cocultured with syngeneic MSCs were infused into the liver
of STZ-diabetic syngeneic recipients or when islets were
cotransplanted under the renal capsule of NODscid mice
with syngeneic MSCs expanded in culture [223]. Other
studies have demonstrated increased mean capillary density
uponco-transplantationofMSCswithpancreaticisletsalong
with improved islet graft function indicating the beneﬁcial
eﬀect of MSC-mediated graft vascularization [224]. In mice,
islets co-transplanted with MSCs maintained a morphology
closely resembling that of islets in the endogenous pancreas,
both in terms of size, and of endocrine and EC distribution.
Superior vascular engraftment as shown by increased EC
numbers within the endocrine tissue as well as improved
graft function demonstrated by normoglycemia achieved in
92% of mice indicated that MSCs profoundly inﬂuenced the
remodeling process, by improving islet revascularization and
maintaining islet organisation [224, 225] .I no r d e rt os t u d y
the eﬀect of MSCs on islet survival and insulin secretion
under hypoxia/reoxygenation- (H/R-) induced injury condi-
tions that are associated with islet graft dysfunction, puriﬁed
rat islets cultured with or without MSCs, were exposed to
hypoxia (O(2) ≤ 1%) for 8h followed by reoxygenation
for 24 and 48h, respectively [226]. MSCs maintained a
higher level of stimulation index (SI) of GSIS in islets in
vitro, protected islets from H/R-induced injury by decreasing
the apoptotic cell ratio and increasing HIF-1α,H O - 1 ,
and COX-2 mRNA expression, and signiﬁcantly increased
insulin expression following islet transplantation. This study
indicated that MSCs could promote anti-apoptotic gene
expression by enhancing their resistance to H/R-induced
apoptosis and dysfunction providing an experimental basis
for the therapeutic use of this strategy for enhancing islet
function.
3.Insulin-Secretingβ-Cell Generation from
Stem Cells for Replacement Therapy in T1D.
Apart from the beneﬁcial therapeutic role of stem cells in
immunomodulation and promoting vasculogenesis follow-
ing islet transplantation, they may also play an important
role in regeneration of β-cells. The concept of regenerating
β-cells from a self renewing, expandable stock of pluripotent
ESCs, pancreas-derived multipotent progenitor/stem cells,
extrapancreatic adult stem cells (e.g, BMSCs, neural pro-
genitor cells, UCB-SCs, etc.) or iPSCs into large quantities
of cells with an insulin-expressing phenotype in vitro16 Journal of Transplantation
oﬀers an attractive alternative source for β-cell replacement
therapy [227, 228]. While the immunosuppressive, anti-
inﬂammatory, and angiogenic properties of MSCs are of
tremendous advantage, the ability of iPSCs to generate
an unlimited supply of clinically compliant, functional
autologous β-cells provides a deﬁnitive solution to the
cited limitations of islet transplantation, namely, shortage
of donor pancreases and the harmful side eﬀects of chronic
immunosuppressive therapy.
Based on sequential exposure of human ESCs to epi-
genetic signals that mimic in vivo pancreatic development,
insulin-producing cells can be generated from ESCs [227,
229–231]. These diﬀerentiated cells display architectural
similarity to mature primary islets, are capable of synthesiz-
ing insulin, glucagon, somatostatin, pancreatic polypeptide
and ghrelin [229, 230], reverse hyperglycemia in diabetic
mice, prolong graft survival, and respond successfully to
glucose challenge in glucose-tolerant tests (GTT) providing
deﬁnitive evidence of the ability of hESCs to serve as a
renewable source of insulin-secreting β-cells for diabetes
cell-replacement therapies. The risk of teratoma formation
and tumor formation and the diﬃculty of purifying the
diﬀerentiated progeny are major drawbacks. Multipotent
BM-MSCs are plastic-adherent cells, expressing surface
markers such as CD90, CD73, CD105, CD44, and CD29
that can be isolated and expanded with high eﬃciency in
culture and can diﬀerentiate into cells of connective tissue
lineages,includingbone,fat,cartilage,andmuscle[232].The
capacity of BM-MSCs to generate insulin-producing cells
[232, 233] capable of producing and releasing insulin in a
glucose-dependent manner and normalizing hyperglycemia
upon transplantation into a diabetic mice [234, 235] while
at the same time abrogating immune injury, altering T
cell cytokine pattern toward IL-10/IL-13 production and
preserving CD4+/CD8+ FOXP3+ Tregs in the periphery
[236] make BM-MSCs an invaluable tool in β-cells replace-
ment therapies. In vivo diﬀerentiation of hUCB cells into
β-cells following transplantation into STZ-induced diabetic
immunocompromised [237, 238]o rN O Dm i c e[ 239] indi-
cates the potential role of these cells in β-cell replacement
therapy. iPSCs may be derived from autologous somatic cells
by ectopic expression of the transcription factors Oct4, Sox2,
c-myc,a n dKlf4 or oct3/4, sox2, nanog, lin28 [240]a n da r e
molecularly and functionally highly similar to ESCs [241],
oﬀering an important alternative to replenish β-cell supply
[242]whilesimultaneouslyobviatingimmuneconcernssuch
as rejection and chronic immunosuppression. Most human
iPSC lines can be induced into Pdx1-positive progenitor cells
and further diﬀerentiated into pancreatic lineage cells using
a stepwise induction strategy [243, 244]. Other alternative
sources of β-cells include intrahepatic biliary epithelial
cells and gall bladder epithelium [245], human neural
progenitor cells [246], hepatic oval cells [247]p l a c e n t a -
derived multipotent stem cells [248], and adult pancreatic
stem/progenitor cells [249, 250]. The common embryonic
origin of liver and pancreas, similarities in their glucose-
sensing systems, mutually expressed transcription factors,
and the high level of developmental plasticity exhibited by
adult human liver cells indicate the therapeutic potential
of liver stem cells/hepatocytes as a source of pancreatic
progenitor tissue. Several studies have demonstrated repro-
gramming of hepatocytes into function insulin-producing
cells by expression of the Pdx1 or its superactive form Pdx1-
VP16 fusion protein either alone or in combination with
other pancreatic transcription factors using ﬁrst generation,
nontoxic, transiently expressed adenoviral vectors under
conditions of hyperglycemia or hepatic regeneration [251–
253]. However, although the potential of stem cells in the
future of T1D interventional therapies is immense, the
accompanying risk of mutagenesis, teratoma and tumor
formation needs to be stringently addressed. For now
it appears that the combination of multiple therapeutic
avenues is required to achieve the dream of permanently
reversing/preventing T1D.
4. Conclusion
Areas of current research include the development of
less toxic immunosuppressive regimens, the suppression of
inﬂammatory responses immediately following transplanta-
tion, the identiﬁcation of an optimal anatomical site for islet
infusion, and the possibility of encapsulating transplanted
islets to protect them from the alloimmune response. The
generation of Tregs with deﬁned alloantigen speciﬁcity could
provide dynamic control of rejection responses and oﬀer a
potential route to permanent graft survival without the need
for life-long nonspeciﬁc immunosuppression. Regeneration
of β-cells utilizing every kind cell from the pancreas, stem
c e l l sa sw e l la sc e l l sf r o ma l t e r n a t es o u r c e s ,f o l l o w e db y
transplantation using immunosuppressive regimens that
would ensure maximal graft survival through protection
from hypoxic and immune insults is an exciting alternative.
Clinical islet transplantation represents a possible deﬁnitive
intervention for patients with T1D and with signiﬁcant
inroads in the branches of stem cell therapy, immunomod-
ulation and gene therapy, the prospect of translating these
beneﬁcial interventions into clinical applications that pro-
mote successful long-term functional islet graft survival
appears within reach.
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